Latest News

STAT Plus: Epizyme seeks early approval for drug to treat ultra-rare tumors

Eleven years after it was founded, the Cambridge, Mass.-based biopharmaceutical startup Epizyme on Thursday sought early approval of an experimental medicine to treat an ultra-rare form of cancerous tumors. If successful, the drug would be the company’s first to reach the market.

Based on encouraging results from a midstage clinical trial, Epizyme asked the Food and Drug Administration for accelerated approval of tazemetostat for epithelioid sarcoma, a cancer most often diagnosed in young adults. The company will discuss the data Monday at the annual meeting of the American Society of Clinical Oncology in Chicago.

Source link

Related posts

Researchers suggest balanced reporting of sports head injuries


“Tic-Tac-Toe” tackles Alzheimer’s disease


Healthy People Could Die From Vaping — Here’s Why


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy